CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt

Journal of Hepatology

Volumn 62, Issue 2, 2015, Pages 332-339

  Berres, Marie Luise ^a   Asmacher, Sonja ^b   Lehmann, Jennifer ^b   Jansen, Christian ^b   Görtzen, Jan ^b   Klein, Sabine ^b   Meyer, Carsten ^b   Strunk, Holger M ^b   Fimmers, Rolf ^b   Tacke, Frank ^a   Strassburg, Christian P ^b   Trautwein, Christian ^a   Sauerbruch, Tilman ^b   Wasmuth, Hermann Elard ^a   Trebicka, Jonel ^b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Chemokines; Cirrhosis; Portal hypertension; Transjugular intrahepatic portosystemic shunt

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLINESTERASE; CREATININE; CXCL9 CHEMOKINE; GAMMA GLUTAMYLTRANSFERASE; NITROGEN; SODIUM; UREA; BIOLOGICAL MARKER; CXCL9 PROTEIN, HUMAN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALCOHOL CONSUMPTION; ALCOHOL LIVER CIRRHOSIS; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHILD PUGH SCORE; CHOLINESTERASE BLOOD LEVEL; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DOPPLER FLOWMETRY; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMODYNAMIC PARAMETERS; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER VEIN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PORTAL HYPERTENSION; PORTAL VEIN BLOOD; PORTAL VEIN BLOOD PRESSURE; PREDICTIVE VALUE; PRESSURE GRADIENT; PRESSURE MEASUREMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SODIUM BLOOD LEVEL; SODIUM EXCRETION; SODIUM URINE LEVEL; SURVIVAL TIME; THROMBOCYTE COUNT; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; UREA NITROGEN BLOOD LEVEL; BLOOD; COMPLICATION; HYPERTENSION, PORTAL; MIDDLE AGED; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ADULT; AGED; BIOLOGICAL MARKERS; CHEMOKINE CXCL9; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84922210408     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.09.032     Document Type: Article

References (37)

1. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-1669.
2. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. Portal hypertension. J Hepatol 2000; 32: 141-156.
3. Sahin H, Trautwein C, Wasmuth HE. Functional role of chemokines in liver disease models. Nat Rev Gastroenterol Hepatol 2010; 7: 682-690.
4. Wasmuth HE, Tacke F, Trautwein C. Chemokines in liver inflammation and fibrosis. Semin Liver Dis 2010; 30: 215-225.
5. Manousou P, Kolios G, Drygiannakis I, Koulentaki M, Pyrovolaki K, Voumvouraki A, et al. CXCR3 axis in patients with primary biliary cirrhosis: A possible novel mechanism of the effect of ursodeoxycholic acid. Clin Exp Immunol 2013; 172: 9-15.
6. Sahin H, Borkham-Kamphorst E, Kuppe C, Zaldivar MM, Grouls C, Al-samman M, et al. Chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice. Hepatology 2012; 55: 1610-1619.
7. Jouan L, Chatel-Chaix L, Melancon P, Rodrigue-Gervais IG, Raymond VA, Selliah S, et al. Targeted impairment of innate antiviral responses in the liver of chronic hepatitis C patients. J Hepatol 2012; 56: 70-77.
8. Larrubia JR, Benito-Martinez S, Calvino M, Sanz-de-Villalobos E, Parra-Cid T. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J Gastroenterol 2008; 14: 7149-7159.
9. Zeremski M, Petrovic LM, Chiriboga L, Brown QB, Yee HT, Kinkhabwala M, et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 2008; 48: 1440-1450.
10. Zhai Y, Shen XD, Gao F, Zhao A, Freitas MC, Lassman C, et al. CXCL10 regulates liver innate immune response against ischemia and reperfusion injury. Hepatology 2008; 47: 207-214.
11. Chuang YH, Lian ZX, Cheng CM, Lan RY, Yang GX, Moritoki Y, et al. Increased levels of chemokine receptor CXCR3 and chemokines IP-10 and MIG in patients with primary biliary cirrhosis and their first degree relatives. J Autoimmun 2005; 25: 126-132.
12. Apolinario A, Majano PL, Alvarez-Perez E, Saez A, Lozano C, Vargas J, et al. Increased expression of T cell chemokines and their receptors in chronic hepatitis C: Relationship with the histological activity of liver disease. Am J Gastroenterol 2002; 97: 2861-2870.
13. Berres ML, Trautwein C, Schmeding M, Eurich D, Tacke F, Bahra M, et al. Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection. Hepatology 2011; 53: 596-603.
14. Moura AS, Carmo RA, Teixeira AL, Leite VH, Rocha MO. Soluble inflammatory markers as predictors of liver histological changes in patients with chronic hepatitis C virus infection. Eur J Clin Microbiol Infect Dis 2010; 29: 1153-1161.
15. Wasmuth HE, Lammert F, Zaldivar MM, Weiskirchen R, Hellerbrand C, Scholten D, et al. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology 2009; 137: 309-319, 319 e301-e303.
16. Zeremski M, Dimova R, Astemborski J, Thomas DL, Talal AH. CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C. J Infect Dis 2011; 204: 832-836.
17. Zeremski M, Dimova R, Brown Q, Jacobson IM, Markatou M, Talal AH. Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J Infect Dis 2009; 200: 1774-1780.
18. Berenguer J, Fernandez-Rodriguez A, Jimenez-Sousa MA, Cosin J, Zarate P, Micheloud D, et al. High plasma CXCL10 levels are associated with HCVgenotype 1, and higher insulin resistance, fibrosis, and HIV viral load in HIV/HCV coinfected patients. Cytokine 2012; 57: 25-29.
19. Tacke F, Zimmermann HW, Berres ML, Trautwein C, Wasmuth HE. Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases. Liver Int 2011; 31: 840-849.
20. Ren X, Kennedy A, Colletti LM. CXC chemokine expression after stimulation with interferon-gamma in primary rat hepatocytes in culture. Shock 2002; 17: 513-520.
21. Sahin H, Borkham-Kamphorst E, do ON, Berres ML, Kaldenbach M, Schmitz P, et al. Proapoptotic effects of the chemokine, CXCL 10 are mediated by the noncognate receptor TLR4 in hepatocytes. Hepatology 2013; 57: 797-805.
22. Abe T, Fukuhara T, Wen X, Ninomiya A, Moriishi K, Maehara Y, et al. CD44 participates in IP-10 induction in cells in which hepatitis C virus RNA is replicating, through an interaction with Toll-like receptor 2 and hyaluronan. J Virol 2012; 86: 6159-6170.
23. Hintermann E, Bayer M, Pfeilschifter JM, Luster AD, Christen U. CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation. J Autoimmun 2010; 35: 424-435.
24. Harvey CE, Post JJ, Palladinetti P, Freeman AJ, Ffrench RA, Kumar RK, et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 2003; 74: 360-369.
25. Helbig KJ, Ruszkiewicz A, Semendric L, Harley HA, McColl SR, Beard MR. Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation. Hepatology 2004; 39: 1220-1229.
26. Friedman BH, Wolf JH, Wang L, Putt ME, Shaked A, Christie JD, et al. Serum cytokine profiles associated with early allograft dysfunction in patients undergoing liver transplantation. Liver Transpl 2012; 18: 166-176.
27. Reiberger T, Aberle JH, Kundi M, Kohrgruber N, Rieger A, Gangl A, et al. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection. Antivir Ther 2008; 13: 969-976.
28. Chao Y, Li CP, Chau GY, Chen CP, King KL, Lui WY, et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 2003; 10: 355-362.
29. Kimball P, McDougan F, Stirling R. CXCR3 expression elevated on peripheral CD8(+) lymphocytes from HIV/HCV coinfected individuals. Viral Immunol 2011; 24: 441-448.
30. Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: A phase II study. Gut 2000; 47: 288-295.
31. Brensing KA, Horsch M, Textor J, Schiedermaier P, Raab P, Schepke M, et al. Hemodynamic effects of propranolol and nitrates in cirrhotics with transjugular intrahepatic portosystemic stent-shunt. Scand J Gastroenterol 2002; 37: 1070-1076.
32. Trebicka J, Krag A, Gansweid S, Appenrodt B, Schiedermaier P, Sauerbruch T, et al. Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt. Eur J Gastroenterol Hepatol 2011; 23: 1218-1225.
33. Trebicka J, Krag A, Gansweid S, Schiedermaier P, Strunk HM, Fimmers R, et al. Soluble TNF-alpha-receptors I are prognostic markers in TIPS-treated patients with cirrhosis and portal hypertension. PLoS One 2013; 8: E83341.
34. Erhardt A, Wegscheid C, Claass B, Carambia A, Herkel J, Mittrucker HW, et al. CXCR3 deficiency exacerbates liver disease and abrogates tolerance in a mouse model of immune-mediated hepatitis. J Immunol 2011; 186: 5284-5293.
35. Nishioji K, Okanoue T, Itoh Y, Narumi S, Sakamoto M, Nakamura H, et al. Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes. Clin Exp Immunol 2001; 123: 271-279.
36. Wong F. Recent advances in our understanding of hepatorenal syndrome. Nat Rev Gastroenterol Hepatol 2012; 9: 382-391.
37. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-onchronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144: 1426-1437, 1437 e1421-e1429.